Company news
Noxopharm Ltd. news in 2023
Noxopharm Ltd.'s news releases, calls and decks from 2023, newest first.
Noxopharm Enhances Cash Position via R&D Rebate
November 15, 2023
Noxopharm 2023 AGM Corporate Presentation
November 15, 2023
mRNA Vaccine Enhancer Shows Inflammation Reduction
October 17, 2023
September 2023 Activities Report and Appendix 4C
October 12, 2023
Response to ASX Query
October 8, 2023
US FDA grants Orphan Drug Designation for CRO-67
October 3, 2023
Trading Halt
October 3, 2023
Pause in Trading
October 3, 2023
Latest CRO-67 data shows success in reducing cancer growth
September 27, 2023
Appendix 4E and Audited Financial Statements
August 31, 2023
June 2023 Activities Report and Appendix 4C
July 13, 2023
IONIC Trial Abstract Published at ASCO
May 25, 2023
Study results show new Sofra drug reduces inflammation
May 18, 2023
March 2023 Quarterly Activities Report and Appendix 4C
April 23, 2023
Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
April 5, 2023
Noxopharm Announces Novel mRNA Vaccine Enhancer
March 27, 2023
Appendix 4D and Half Year 2023 Financial Report
February 24, 2023
December 2022 Quarterly Activities Report and Appendix 4C
January 26, 2023
DARRT-2 Trial Efficacy Phase to Commence
January 16, 2023
Decks in 2023
- Shareholder Meeting (November 2023)
Shareholder meeting · 37 slides · Nov 16, 2023